Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell-based treatments for challenging disease indications to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.funded-trials-51.png

CIRM Clinical Dashboard

Disease Areas Investigator Organizationsort descending Phase Trial Status Targeted Enrollment Detail
Paul Finnegan Angiocrine Bioscience, Inc. Phase 1 Launching N/A
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Launching N/A
Edward Wirth Asterias Biotherapeutics Phase 1/2 Completed 25
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Recruiting 200
Douglas Losordo Caladrius Biosciences Phase 2 Active, not recruiting 113
Robert Dillman Caladrius Biosciences Phase 3 Terminated 250
Kristen Johnson Calibr Phase 1 Recruiting 60
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 12
Rachel Smith Capricor, Inc Phase 2 Terminated 156
Linda Marban Capricor, Inc Phase 2 Completed 25
  • Pulmonary Hypertension
 Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Recruiting 26
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 18
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Launching N/A
Christine Brown City of Hope, Beckman Research Institute Phase 1 Recruiting 92
Joseph Rosenthal City of Hope, Beckman Research Institute Phase 1 Recruiting 6
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Mark Chao Forty Seven Inc. Phase 1/2 Recruiting 112
  • Leukemia, Acute Myeloid (AML)
 Mark Chao Forty Seven Inc. Phase 1 Recruiting 96
Jane Lebkowski Geron Corporation Phase 1 Completed 5
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
Henry Klassen jCyte, Inc Phase 2 Active, not recruiting 84
Scott Batty Medeor Therapeutics, Inc. Phase 3 Recruiting 75
  • Leukemia, Acute Myeloid (AML)
 Colleen Delaney Nohla Therapeutics Inc Phase 2 Active, not recruiting 146
  • Multiple Myeloma
 Matthew Spear Poseida Therapeutics, Inc. Phase 1 Recruiting 40
Damien Bates SanBio, Inc. Phase 2 Active, not recruiting 156
  • Beta Thalassemia
 Ed Conner Sangamo BioSciences, Inc. Phase 1/2 Recruiting 6
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
Samuel Strober Stanford University Phase 1 Active, not recruiting 15
Crystal Mackall Stanford University Phase 1 Recruiting 57
Everett Meyer Stanford University Phase 1 Launching N/A
Judith Shizuru Stanford University Phase 1/2 Recruiting 90
Irving Weissman Stanford University Phase 1 Completed 88
Nancy Lane University of California, Davis Phase 1/2 Recruiting 50
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
  • X-linked Chronic Granulomatous Disease
 Donald Kohn University of California, Los Angeles Phase 1/2 Recruiting 10
Steven Dubinett University of California, Los Angeles Phase 1 Launching N/A
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
Donald Kohn University of California, Los Angeles Phase 2 Active, not recruiting 10
Dennis Slamon University of California, Los Angeles Phase 1 Recruiting 48
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 156
Thomas Kipps University of California, San Diego Phase 1 Completed 26
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
 Morton Cowan University of California, San Francisco Phase 1 Launching N/A
  • Alpha Thalassemia Major
 Tippi MacKenzie University of California, San Francisco Phase 1 Recruiting 10
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
Howard Foyt ViaCyte, Inc. Phase 1/2 Active, not recruiting 69
Howard Foyt ViaCyte, Inc. Phase 1/2 Recruiting 55